Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 8 | 2014 | 935 | 0.490 |
Why?
|
| Poliovirus Vaccines | 1 | 2012 | 2 | 0.440 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 37 | 0.420 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 59 | 0.410 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 73 | 0.410 |
Why?
|
| Hela Cells | 1 | 2012 | 366 | 0.390 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 33 | 0.380 |
Why?
|
| Universities | 2 | 2012 | 442 | 0.350 |
Why?
|
| Peptides | 1 | 2012 | 320 | 0.340 |
Why?
|
| Peptide Fragments | 1 | 2010 | 308 | 0.320 |
Why?
|
| Biomedical Research | 1 | 2012 | 400 | 0.310 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 803 | 0.230 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2002 | 8 | 0.210 |
Why?
|
| Synaptic Vesicles | 1 | 2002 | 31 | 0.200 |
Why?
|
| Crotonates | 1 | 2021 | 1 | 0.200 |
Why?
|
| Hydroxybutyrates | 1 | 2021 | 2 | 0.200 |
Why?
|
| Toluidines | 1 | 2021 | 4 | 0.200 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2021 | 12 | 0.200 |
Why?
|
| Nitriles | 1 | 2021 | 69 | 0.190 |
Why?
|
| Quercetin | 2 | 2012 | 45 | 0.180 |
Why?
|
| Cell Movement | 3 | 2012 | 571 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 251 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 234 | 0.170 |
Why?
|
| Prostate | 2 | 2010 | 154 | 0.170 |
Why?
|
| DNA Damage | 2 | 2012 | 352 | 0.160 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1198 | 0.160 |
Why?
|
| MicroRNAs | 2 | 2014 | 426 | 0.140 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 2231 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 1039 | 0.130 |
Why?
|
| Alabama | 2 | 2012 | 51 | 0.130 |
Why?
|
| Protein Binding | 2 | 2012 | 972 | 0.120 |
Why?
|
| Humans | 15 | 2021 | 37093 | 0.120 |
Why?
|
| Interinstitutional Relations | 2 | 2013 | 38 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2012 | 444 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.120 |
Why?
|
| Neoplasms | 3 | 2013 | 1103 | 0.110 |
Why?
|
| Minority Health | 1 | 2013 | 88 | 0.110 |
Why?
|
| Poliomyelitis | 1 | 2012 | 7 | 0.110 |
Why?
|
| Receptors, CXCR3 | 1 | 2012 | 31 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2012 | 117 | 0.100 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 73 | 0.100 |
Why?
|
| Cell Cycle | 2 | 2012 | 326 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2012 | 131 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 109 | 0.100 |
Why?
|
| Ruta | 1 | 2011 | 3 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2012 | 366 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2010 | 101 | 0.090 |
Why?
|
| Ethics, Research | 1 | 2010 | 17 | 0.090 |
Why?
|
| Nocodazole | 1 | 2010 | 9 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 182 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 18 | 0.090 |
Why?
|
| Health Status Disparities | 2 | 2013 | 642 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2010 | 50 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1180 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 441 | 0.080 |
Why?
|
| Male | 9 | 2021 | 20025 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1568 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 560 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2012 | 308 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 494 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 269 | 0.080 |
Why?
|
| Communication | 1 | 2010 | 180 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2012 | 808 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 219 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 202 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 416 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 110 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 807 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2011 | 286 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2012 | 681 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 384 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1207 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2012 | 1908 | 0.070 |
Why?
|
| Apoptosis | 2 | 2012 | 1398 | 0.070 |
Why?
|
| Cell Line | 2 | 2010 | 1354 | 0.060 |
Why?
|
| Cell Survival | 2 | 2021 | 864 | 0.060 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2002 | 2 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2002 | 18 | 0.050 |
Why?
|
| Synaptosomes | 1 | 2002 | 21 | 0.050 |
Why?
|
| Exocytosis | 1 | 2002 | 47 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 96 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2002 | 42 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 140 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2012 | 21 | 0.050 |
Why?
|
| Gene Products, tax | 1 | 2021 | 4 | 0.050 |
Why?
|
| HTLV-I Infections | 1 | 2021 | 31 | 0.050 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 33 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 251 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2002 | 120 | 0.050 |
Why?
|
| Cyclin B1 | 2 | 2012 | 16 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 146 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2002 | 128 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 10129 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 88 | 0.050 |
Why?
|
| Aged | 3 | 2021 | 6741 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2012 | 399 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 617 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2002 | 305 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 360 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2012 | 859 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 480 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 928 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 213 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2002 | 517 | 0.040 |
Why?
|
| Mice | 2 | 2010 | 5913 | 0.030 |
Why?
|
| Brain | 1 | 2002 | 1346 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 49 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 108 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 65 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 68 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 77 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 170 | 0.030 |
Why?
|
| Cadherins | 1 | 2012 | 90 | 0.030 |
Why?
|
| Camptothecin | 1 | 2012 | 20 | 0.030 |
Why?
|
| Etoposide | 1 | 2012 | 22 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 55 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 77 | 0.030 |
Why?
|
| Protein Transport | 1 | 2012 | 302 | 0.020 |
Why?
|
| Adult | 2 | 2021 | 11712 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 177 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 5 | 0.020 |
Why?
|
| Animals | 2 | 2010 | 15081 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 92 | 0.020 |
Why?
|
| Morals | 1 | 2010 | 13 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 189 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 626 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 150 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 2011 | 68 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 89 | 0.020 |
Why?
|
| Food-Drug Interactions | 1 | 2010 | 4 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 207 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 58 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 142 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 29 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 601 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 502 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 88 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1378 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 212 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 222 | 0.020 |
Why?
|
| Microtubules | 1 | 2010 | 120 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2010 | 198 | 0.020 |
Why?
|
| Female | 2 | 2021 | 20969 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2379 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1742 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 4268 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1502 | 0.010 |
Why?
|